Author

Enming Yuan

Tsinghua UniversityORCID 0000-0003-0755-9109Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:machine learning (classical)· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Jianyang ZengiD· 2 shared Akshay BhingeiD· 1 shared Alison E. TwelvetreesiD· 1 shared Allan Christian ShawiD· 1 shared Anna Avila· 1 shared Calum HarveyiD· 1 shared Charlotte H. van DijkiD· 1 shared Chengliang Hu· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Jianyang ZengORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicinemedRxivPreprintMar 30, 2024

Antisense oligonucleotide depletion of CCDC146 is a broad-spectrum therapeutic strategy for ALS

Sai Zhang, Tobias Moll, Jasper Rubin-Sigler…·Michael P. Snyder

The paper identifies CCDC146 as a modifier of ALS survival through primary cilia dysfunction and shows ASO targeting of CCDC146 rescues ALS phenotypes in human and mouse models.

5 citations

humanwhole-genome sequencing

𝕏 PostBluesky

Systems BiologySignal Transduction and Targeted TherapyPeer-reviewedApr 24, 2021

A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Yiyue Ge, Tingzhong Tian, Suling Huang…·Jianyang Zeng

This paper presents a data-driven drug repositioning framework that identifies CVL218, a PARP1 inhibitor, as a potential therapeutic for COVID-19 through in silico and experimental validation.

300 citationstop 1%

humanmachine learning (classical)

𝕏 PostBluesky